Novartis | NOVN - Sales Revenues

Stock Price
130.50
Daily Change
2.40 1.87%
Monthly
14.27%
Yearly
33.63%
Q1 Forecast
123.39

Novartis reported $13.91B in Sales Revenues for its fiscal quarter ending in September of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alcon AG USD 2.7B 110M Dec/2025
Almirall EUR 547.63M 12.83M Dec/2025
Amgen USD 9.9B 340M Dec/2025
AstraZeneca USD 15.5B 313M Dec/2025
Autolus Therapeutics Ltd USD 22.61M 1.71M Sep/2025
Bayer EUR 9.66B 1.08B Sep/2025
Biogen USD 2.28B 250M Dec/2025
Bristol-Myers Squibb USD 12.5B 300M Dec/2025
Eli Lilly USD 19.3B 1.7B Dec/2025
Fresenius EUR 5.88B 400M Dec/2025
Fresenius Medical Care EUR 5.07B 180M Dec/2025
Galapagos EUR 900.82M 835.52M Dec/2025
Genmab DKK 5.86B 580M Jun/2025
Gilead Sciences USD 7.93B 130M Dec/2025
GlaxoSmithKline GBP 8.62B 73M Dec/2025
GRIFOLS EUR 1.87B 20M Sep/2025
Hikma Pharmaceutical USD 829M 758M Jun/2025
J&J USD 24.6B 610M Dec/2025
Lonza CHF 3.58B 63M Jun/2025
Merck EUR 5.32B 890M Sep/2025
Merck USD 16.4B 880M Dec/2025
Novartis USD 13.91B 144M Sep/2025
Novartis USD 14.36B 478M Sep/2025
Novo Nordisk DKK 79.14B 4.16B Dec/2025
Orion EUR 695.3M 272.1M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
Philips EUR 5.1B 797M Dec/2025
Recordati EUR 662M 37.65M Dec/2025
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sanofi EUR 11.3B 1.13B Dec/2025
UCB EUR 3.49B 129M Jun/2025